Idiopathic Pulmonary Fibrosis Global Market Report 2025

Global Idiopathic Pulmonary Fibrosis Market Report 2024

Idiopathic Pulmonary Fibrosis Global Market Report 2025 – By Drug Type (Nintedanib, Pirfenidone, Other Drug Types), By Mode Of Action (Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes of Action), By Route Of Administration (Oral, Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Providers), By End Users (Hospitals and Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

Name: Idiopathic Pulmonary Fibrosis Global Market Report 2025
Creator: The Business Research Company
License: https://www.thebusinessresearchcompany.com/privacy-policy

Idiopathic Pulmonary Fibrosis Global Market Report 2025

Report Price : $4490.00 | Pages : | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options

Request a Sample

Request For Discount

Customise Your Report

Item added to cart!

Request For Proposal

Request For Regional Data

FAQs

Need assistance or more information before the purchase?

Enquire Before Buying

Idiopathic Pulmonary Fibrosis Global Market Report 2025

Proud Members Of

Idiopathic Pulmonary Fibrosis Market Definition

Idiopathic pulmonary fibrosis (IPF) is a lung disease characterized by the gradual and continuous deterioration of the tissue encompassing the air sacs, known as alveoli, in the lungs. This condition leads to the accumulation of scar tissue (fibrosis) within the lungs, impeding the efficient transportation of oxygen into the bloodstream.

The main drug types in idiopathic pulmonary fibrosis include nintedanib, pirfenidone, and others. Nintedanib is a medication prescribed for the treatment of specific lung conditions, such as idiopathic pulmonary fibrosis (IPF), an interstitial lung disease with a progressive phenotype, and interstitial lung disease associated with systemic sclerosis. The various modes of action include antifibrotic agents, tyrosine kinase inhibitors, and others with various routes of administration such as oral and parenteral. The various distribution channels include hospital pharmacies, retail pharmacies, and online for the various end users, including hospitals, clinics, and others.

Idiopathic Pulmonary Fibrosis Market Segmentation

The idiopathic pulmonary fibrosis market covered in this report is segmented –

1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types

2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action

3) By Route Of Administration: Oral, Parenteral

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers

5) By End Users: Hospitals And Clinics, Other End Users

Subsegments:

1) By Nintedanib: Indications, Dosage Forms, Administration Routes

2) By Pirfenidone: Indications, Dosage Forms, Administration Routes

3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies

Idiopathic Pulmonary Fibrosis Market Size and growth rate 2025 to 2029: Graph

Idiopathic Pulmonary Fibrosis Market Size 2025 And Growth Rate

The idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $4.15 billion in 2024 to $4.39 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing aging population, limited treatment options, rising disease awareness, healthcare infrastructure development

Idiopathic Pulmonary Fibrosis Market Growth Forecast

The idiopathic pulmonary fibrosis market size is expected to see strong growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to expanded research and development, precision medicine approach, increasing disease incidence, advancements in biomarker development, government initiatives and funding. Major trends in the forecast period include advancements in diagnostic techniques, emergence of targeted therapies, telemedicine and remote monitoring, combination therapies, advancements in lung transplantation.

Book your 30 minutes free consultation with our research experts

Idiopathic Pulmonary Fibrosis Market Driver: Surge In Fibrotic Diseases Propels Growth Of Idiopathic Pulmonary Fibrosis Market

The rise in the prevalence of fibrotic disease is expected to drive the growth of the idiopathic pulmonary fibrosis market going forward. Fibrotic diseases, also known as fibrosis, refer to a group of medical conditions characterized by the excessive formation and accumulation of fibrous connective tissue in various organs or tissues in the body. Idiopathic pulmonary fibrosis drugs help reduce lung fibrosis and inflammation by targeting multiple signaling pathways involved in fibrosis. For instance, in December 2022, according to the American Lung Association, a US-based lung association, there were around 207,000 people affected in the United States and approximately 58,000 new cases of idiopathic pulmonary fibrosis diagnosed each year, which is more common in men than women and mainly affects people over 50 years of age. Therefore, the rise in the prevalence of fibrotic disease drives the idiopathic pulmonary fibrosis market.

Idiopathic Pulmonary Fibrosis Market Driver: Growing Geriatric Population Fuels Expansion Of Idiopathic Pulmonary Fibrosis Market

An increasing geriatric population is expected to boost the growth of the idiopathic pulmonary fibrosis market going forward. The geriatric population refers to the elderly or senior citizens within a given society or population. Aging is associated with structural and functional changes in the lungs, making older individuals more susceptible to respiratory diseases such as IPF. This age-related vulnerability contributes to the overall demand for IPF treatments. For instance, in October 2022, according to the World Health Organization, a US-based specialized health agency, globally, 1 in 6 people will be 60 or older by 2030, and there will be a double amount of individuals in this age group (2.1 billion) by 2050. Therefore, the increasing geriatric population is driving the growth of the idiopathic pulmonary fibrosis market.

Global Idiopathic Pulmonary Fibrosis Market Major Players

Major companies operating in the idiopathic pulmonary fibrosis market include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.

Global Idiopathic Pulmonary Fibrosis Market Trend: Product Innovations Expanding Access And Affordability For Patients In The Idiopathic Pulmonary Fibrosis Market

Product innovation is a key trend gaining popularity in the idiopathic pulmonary fibrosis market. Major companies operating in the idiopathic pulmonary fibrosis market focus on developing innovative products to strengthen their position and gain a competitive advantage. For instance, in May 2022, Sandoz, a Switzerland-based company that manufactures generic and biosimilar medicines, launched a generic version of pirfenidone, which is the first AB-rated equivalent to Genentech's Esbriet, aimed at treating individuals suffering from idiopathic pulmonary fibrosis (IPF). This orally administered prescription medication is now accessible to patients through specialty pharmacies, and eligible patients can benefit from a USD 0 co-pay program.

Global Idiopathic Pulmonary Fibrosis Market Trend: Groundbreaking Anti-Fibrotic Small-Molecule Inhibitor Paving The Way In Idiopathic Pulmonary Fibrosis Treatment

Major companies operating in the idiopathic pulmonary fibrosis (IPF) market are focusing on innovative products, such as anti-fibrotic small-molecule inhibitors, to sustain their position in the market. Anti-fibrotic small-molecule inhibitors refer to a type of pharmaceutical compound designed to target and inhibit the fibrotic processes in the body. For instance, in June 2023, Insilico Medicine, a US-based clinical-stage biotechnology company using generative artificial intelligence (AI), announced the initiation of Phase II clinical trials for INS018_055, the world’s first anti-fibrotic small molecule inhibitor designed through generative AI. This milestone marks the first dose administered to patients in the trial, which is a randomized, double-blind, placebo-controlled study aimed at evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of a 12-week oral dosage of INS018_055 in subjects with idiopathic pulmonary fibrosis (IPF). This innovative approach leverages AI in drug discovery, showcasing a potential advancement in the treatment of idiopathic pulmonary fibrosis (IPF) diseases.

Idiopathic Pulmonary Fibrosis Market Merger And Acquisition: AbbVie Inc. Expands Immunology Portfolio With Acquisition Of DJs Antibodies Ltd

In October 2022, AbbVie Inc., a US-based pharmaceutical company, acquired DJS Antibodies Ltd. for an undisclosed amount. With this acquisition, AbbVie aims to provide new capabilities to enhance its current antibody research endeavors, the potential to increase its immunology portfolio, and a solid foundation for extended research efforts in the dynamic bioscience hub. DJS Antibodies Ltd. is a UK-based biotechnology company that treats idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases.

Regional Outlook For The Global Idiopathic Pulmonary Fibrosis Market

North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the idiopathic pulmonary fibrosis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

What Defines the Idiopathic Pulmonary Fibrosis Market?

The idiopathic pulmonary fibrosis (IPF) market consists of sales of anti-inflammatory, MAPK inhibitors, autotoxin inhibitors and corticosteroids. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Idiopathic Pulmonary Fibrosis Industry?

The idiopathic pulmonary fibrosis market research report is one of a series of new reports from The Business Research Company that provides idiopathic pulmonary fibrosis market statistics, including idiopathic pulmonary fibrosis industry global market size, regional shares, competitors with idiopathic pulmonary fibrosis market share, detailed idiopathic pulmonary fibrosis market segments, market trends, and opportunities, and any further data you may need to thrive in the idiopathic pulmonary fibrosis industry. This idiopathic pulmonary fibrosis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Idiopathic Pulmonary Fibrosis Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2025	$4.39 billion
Revenue Forecast In 2034	$5.74 billion
Growth Rate	CAGR of 7.0% from 2024 to 2033
Base Year For Estimation	2024
Actual Estimates/Historical Data	2019-2024
Forecast Period	2025 - 2029 - 2034
Market Representation	Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered	1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types 2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action 3) By Route Of Administration: Oral, Parenteral 4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers 5) By End Users: Hospitals And Clinics, Other End Users Subsegments: 1) By Nintedanib: Indications, Dosage Forms, Administration Routes 2) By Pirfenidone: Indications, Dosage Forms, Administration Routes 3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled	F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Sanofi S.A., Gilead Sciences Inc., Toray Industries Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Sun Pharmaceutical Industries Limited, Shionogi and Co. Ltd., Cipla Inc., Zydus Lifesciences Ltd., Chong Kun Dang Pharmaceutical Corp., Kyorin Pharmaceutical Co. Ltd., Galapagos NV, Veracyte Inc., Genentech Inc., FibroGen Inc., GNI Group Ltd., Pliant Therapeutics Inc., Pulmatrix Inc., Galimedix Therapeutics Inc., Avalyn Pharma Inc., MediciNova Inc., Liminal BioSciences Inc., Beijing Continent Pharmaceuticals Company, Galecto Inc.
Customization Scope	Request for Sample
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

2. Idiopathic Pulmonary Fibrosis Market Characteristics

3. Idiopathic Pulmonary Fibrosis Market Trends And Strategies

4. Idiopathic Pulmonary Fibrosis Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Idiopathic Pulmonary Fibrosis Growth Analysis And Strategic Analysis Framework

5.1. Global Idiopathic Pulmonary Fibrosis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

5.2. Analysis Of End Use Industries

5.3. Global Idiopathic Pulmonary Fibrosis Market Growth Rate Analysis

5.4. Global Idiopathic Pulmonary Fibrosis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

5.5. Global Idiopathic Pulmonary Fibrosis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

5.6. Global Idiopathic Pulmonary Fibrosis Total Addressable Market (TAM)

6. Idiopathic Pulmonary Fibrosis Market Segmentation

6.1. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Nintedanib

Pirfenidone

Other Drug Types

6.2. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Antifibrotic Agents

Tyrosine Kinase Inhibitors

Other Modes Of Action

6.3. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Oral

Parenteral

6.4. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospital Pharmacies

Retail Pharmacies

Online Providers

6.5. Global Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Hospitals And Clinics

Other End Users

6.6. Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Nintedanib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Indications

Dosage Forms

Administration Routes

6.7. Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Pirfenidone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Indications

Dosage Forms

Administration Routes

6.8. Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Specific Agents Or Classes

Emerging Therapies

Combination Therapies

7. Idiopathic Pulmonary Fibrosis Market Regional And Country Analysis

7.1. Global Idiopathic Pulmonary Fibrosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

7.2. Global Idiopathic Pulmonary Fibrosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Idiopathic Pulmonary Fibrosis Market

8.1. Asia-Pacific Idiopathic Pulmonary Fibrosis Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

8.2. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.3. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8.4. Asia-Pacific Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Idiopathic Pulmonary Fibrosis Market

9.1. China Idiopathic Pulmonary Fibrosis Market Overview

9.2. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.3. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

9.4. China Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Idiopathic Pulmonary Fibrosis Market

10.1. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.2. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

10.3. India Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Idiopathic Pulmonary Fibrosis Market

11.1. Japan Idiopathic Pulmonary Fibrosis Market Overview

11.2. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.3. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11.4. Japan Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Idiopathic Pulmonary Fibrosis Market

12.1. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.2. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12.3. Australia Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Idiopathic Pulmonary Fibrosis Market

13.1. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.2. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13.3. Indonesia Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Idiopathic Pulmonary Fibrosis Market

14.1. South Korea Idiopathic Pulmonary Fibrosis Market Overview

14.2. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.3. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14.4. South Korea Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Idiopathic Pulmonary Fibrosis Market

15.1. Western Europe Idiopathic Pulmonary Fibrosis Market Overview

15.2. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.3. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15.4. Western Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Idiopathic Pulmonary Fibrosis Market

16.1. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.2. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16.3. UK Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Idiopathic Pulmonary Fibrosis Market

17.1. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.2. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17.3. Germany Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Idiopathic Pulmonary Fibrosis Market

18.1. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.2. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18.3. France Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Idiopathic Pulmonary Fibrosis Market

19.1. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.2. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19.3. Italy Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Idiopathic Pulmonary Fibrosis Market

20.1. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.2. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20.3. Spain Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Idiopathic Pulmonary Fibrosis Market

21.1. Eastern Europe Idiopathic Pulmonary Fibrosis Market Overview

21.2. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.3. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21.4. Eastern Europe Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Idiopathic Pulmonary Fibrosis Market

22.1. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.2. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22.3. Russia Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Idiopathic Pulmonary Fibrosis Market

23.1. North America Idiopathic Pulmonary Fibrosis Market Overview

23.2. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.3. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23.4. North America Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Idiopathic Pulmonary Fibrosis Market

24.1. USA Idiopathic Pulmonary Fibrosis Market Overview

24.2. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.3. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24.4. USA Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Idiopathic Pulmonary Fibrosis Market

25.1. Canada Idiopathic Pulmonary Fibrosis Market Overview

25.2. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.3. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25.4. Canada Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Idiopathic Pulmonary Fibrosis Market

26.1. South America Idiopathic Pulmonary Fibrosis Market Overview

26.2. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.3. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26.4. South America Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Idiopathic Pulmonary Fibrosis Market

27.1. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.2. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27.3. Brazil Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Idiopathic Pulmonary Fibrosis Market

28.1. Middle East Idiopathic Pulmonary Fibrosis Market Overview

28.2. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.3. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28.4. Middle East Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Idiopathic Pulmonary Fibrosis Market

29.1. Africa Idiopathic Pulmonary Fibrosis Market Overview

29.2. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.3. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29.4. Africa Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Idiopathic Pulmonary Fibrosis Market Competitive Landscape And Company Profiles

30.1. Idiopathic Pulmonary Fibrosis Market Competitive Landscape

30.2. Idiopathic Pulmonary Fibrosis Market Company Profiles

30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

30.2.3. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Idiopathic Pulmonary Fibrosis Market Other Major And Innovative Companies

31.1. Sanofi S.A.

31.2. Gilead Sciences Inc.

31.3. Toray Industries Inc.

31.4. Boehringer Ingelheim International GmbH

31.5. Viatris Inc.

31.6. Sun Pharmaceutical Industries Limited

31.7. Shionogi and Co. Ltd.

31.8. Cipla Inc.

31.9. Zydus Lifesciences Ltd.

31.10. Chong Kun Dang Pharmaceutical Corp.

31.11. Kyorin Pharmaceutical Co. Ltd.

31.12. Galapagos NV

31.13. Veracyte Inc.

31.14. Genentech Inc.

31.15. FibroGen Inc.

32. Global Idiopathic Pulmonary Fibrosis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Idiopathic Pulmonary Fibrosis Market

34. Recent Developments In The Idiopathic Pulmonary Fibrosis Market

35. Idiopathic Pulmonary Fibrosis Market High Potential Countries, Segments and Strategies

35.1 Idiopathic Pulmonary Fibrosis Market In 2029 - Countries Offering Most New Opportunities

35.2 Idiopathic Pulmonary Fibrosis Market In 2029 - Segments Offering Most New Opportunities

35.3 Idiopathic Pulmonary Fibrosis Market In 2029 - Growth Strategies

35.3.1 Market Trend Based Strategies

35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations

36.2. Currencies

36.3. Historic And Forecast Inflation Rates

36.4. Research Inquiries

36.5. The Business Research Company

36.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Historic Market Growth, 2019-2024, $ Billion

Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Table 3: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 4: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 5: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 6: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 7: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 8: Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Nintedanib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 9: Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Pirfenidone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 10: Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 11: Global Idiopathic Pulmonary Fibrosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 12: Global Idiopathic Pulmonary Fibrosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 13: Asia-Pacific, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 14: Asia-Pacific, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 15: Asia-Pacific, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 16: China, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 17: China, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 18: China, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 19: India, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 20: India, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 21: India, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 22: Japan, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 23: Japan, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 24: Japan, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 25: Australia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 26: Australia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 27: Australia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 28: Indonesia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 29: Indonesia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 30: Indonesia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 31: South Korea, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 32: South Korea, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 33: South Korea, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 34: Western Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 35: Western Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 36: Western Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 37: UK, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 38: UK, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 39: UK, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 40: Germany, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 41: Germany, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 42: Germany, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 43: France, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 44: France, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 45: France, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 46: Italy, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 47: Italy, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 48: Italy, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 49: Spain, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 50: Spain, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 51: Spain, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 52: Eastern Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 53: Eastern Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 54: Eastern Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 55: Russia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 56: Russia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 57: Russia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 58: North America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 59: North America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 60: North America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 61: USA, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 62: USA, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 63: USA, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 64: Canada, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 65: Canada, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 66: Canada, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 67: South America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 68: South America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 69: South America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 70: Brazil, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 71: Brazil, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 72: Brazil, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 73: Middle East, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 74: Middle East, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 75: Middle East, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 76: Africa, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 77: Africa, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 78: Africa, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Table 79: F. Hoffmann-La Roche Ltd. Financial Performance

Table 80: Merck & Co. Inc. Financial Performance

Table 81: Novartis AG Financial Performance

Table 82: Bristol-Myers Squibb Company Financial Performance

Table 83: AstraZeneca PLC Financial Performance

List Of Figures

Figure 1: Global Historic Market Growth, 2019-2024, $ Billion

Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion

Figure 3: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 4: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 5: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 6: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 7: Global Idiopathic Pulmonary Fibrosis Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 8: Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Nintedanib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 9: Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Pirfenidone, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 10: Global Idiopathic Pulmonary Fibrosis Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 11: Global Idiopathic Pulmonary Fibrosis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 12: Global Idiopathic Pulmonary Fibrosis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 13: Asia-Pacific, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 14: Asia-Pacific, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 15: Asia-Pacific, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 16: China, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 17: China, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 18: China, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 19: India, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 20: India, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 21: India, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 22: Japan, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 23: Japan, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 24: Japan, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 25: Australia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 26: Australia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 27: Australia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 28: Indonesia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 29: Indonesia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 30: Indonesia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 31: South Korea, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 32: South Korea, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 33: South Korea, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 34: Western Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 35: Western Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 36: Western Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 37: UK, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 38: UK, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 39: UK, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 40: Germany, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 41: Germany, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 42: Germany, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 43: France, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 44: France, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 45: France, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 46: Italy, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 47: Italy, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 48: Italy, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 49: Spain, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 50: Spain, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 51: Spain, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 52: Eastern Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 53: Eastern Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 54: Eastern Europe, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 55: Russia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 56: Russia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 57: Russia, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 58: North America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 59: North America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 60: North America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 61: USA, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 62: USA, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 63: USA, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 64: Canada, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 65: Canada, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 66: Canada, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 67: South America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 68: South America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 69: South America, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 70: Brazil, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 71: Brazil, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 72: Brazil, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 73: Middle East, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 74: Middle East, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 75: Middle East, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 76: Africa, Idiopathic Pulmonary Fibrosis Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 77: Africa, Idiopathic Pulmonary Fibrosis Market, Segmentation By Mode Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 78: Africa, Idiopathic Pulmonary Fibrosis Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

Figure 79: F. Hoffmann-La Roche Ltd. Financial Performance

Figure 80: Merck & Co. Inc. Financial Performance

Figure 81: Novartis AG Financial Performance

Figure 82: Bristol-Myers Squibb Company Financial Performance

Figure 83: AstraZeneca PLC Financial Performance

Forecasting Till 2030: Opportunities And Strategies In The Global Value Based Care Payment Market – Includes Value Based Care Payment Market Analysis

How Will The Nuclear Medicine Market Grow In 2022?

What Is The Pediatric Imaging Market Overview In 2022?

Latest Healthcare Technology Management Market Growth Study 2022-2026 By The Business Research Company

The Business Research Company offers the hospital acquired infection control market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the multiplex assays market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the healthcare it consulting market research report 2022 with industry size, share, segments and market growth

The Business Research Company offers the renal biomarkers market research report 2022 with industry size, share, segments and market growth

Pulmonary Arterial Hypertension Global Market Report 2025 – By Drug Class (Endothelin Receptor Antagonists (ERAs), PDE-5 Inhibitors, Prostacyclin and Prostacyclin Analogs, SGC Stimulators), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), By Distribution channel (Retail, Online) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Overactive Bladder Treatment Global Market Report 2025 – By Diseases Type (Idiopathic Bladder Overactivity, Neurogenic Bladder Overactivity), By Therapy (Anticholinergics, Mirabegron, Neurostimulation, Intravesical Instillation, Other Therapies), By Distribution Channel (Hospital Pharmacies, Drug Stores And Retail Pharmacies, Online Providers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Constipation Treatment Global Market Report 2025 – By Therapeutic Types (Laxatives, Chloride Channel Activators, Peripherally Acting Mu-Opioid Receptor Antagonists, GC-C (Guanylate Cyclase-C) Agonists, Other Therapeutics), By Disease Type (Chronic Idiopathic Constipation (CIC), Irritable Bowel Syndrome With Constipation (IBS-C), Opioid-Induced Constipation (OIC)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Generic Musculoskeletal Disorders Drugs Global Market Report 2025 – By Treatment Type (Medication, Therapy, Surgery, Other Treatment Types), By Disorder Type (Osteoarthritis, Rheumatoid Arthritis, Spondylarthritis, Juvenile Idiopathic Arthritis, Psoriatic Arthritis, Fibromyalgia, Other Disorder Types), By Route of Administration (Oral, Parenteral, Other Routes), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store, Online Pharmacy) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Tumor Necrosis Factor Inhibitor Drugs Global Market Report 2025 – By Product Type (Humira, Enbrel, Remicade, Simponi/Simponi Aria, Cimzia, Biosimilars ), By Route Of Administration (Subcutaneous Injection, Intravenous Injection ), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies ), By Application (Rheumatoid Arthritis, Psoriasis, Psoriatic Arthritis, Crohn’s Disease, Ulcerative Colitis, Ankylosing Spondylitis, Juvenile Idiopathic Arthritis, Hidradenitis Suppurativa, Other Applications ) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Plasma Protein Therapeutics Global Market Report 2025 – By Product (Immunoglobulin, Albumin, Coagulation Factor, C1-esterase Inhibitors, Other Products), By Route Of Administration (Intravenous, Subcutaneous), By Applications (Primary Immunodeficiency Disorder (PID), Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency, Hereditary Angioedema, Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Immunoglobulins Global Market Report 2025 – By Product (IGG, IGA, IGM, IGE, IGD. ), By Mode Of Delivery (Intravenous Mode of Delivery, Subcutaneous Mode of Delivery), By Application (Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy (CIDP), Immunodeficiency Disease, Myasthenia Gravis, Idiopathic thrombocytopenic purpura (ITP), Other Applications) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Gastroparesis Global Market Report 2025 – By Treatment Modality (Medications, Dietary Modifications, Medical Devices, Other Therapies), By Gastroparesis Type (Idiopathic, Diabetic, Post- Surgical, Other Types), By Patient Demographics (Pediatric Gastroparesis, Adult Gastroparesis), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Other Distribution Channels), By End User (Hospitals And Clinics, Ambulatory Surgical Centers, Home Care Settings) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Idiopathic Pulmonary Fibrosis market?

How will the Idiopathic Pulmonary Fibrosis market drivers and restraints affect the market dynamics? What forces will shape the Idiopathic Pulmonary Fibrosis industry going forward?

The Idiopathic Pulmonary Fibrosis market major growth driver - Surge In Fibrotic Diseases Propels Growth Of Idiopathic Pulmonary Fibrosis Market. For further insights on the Idiopathic Pulmonary Fibrosis market, request a sample here

What is the forecast market size or the forecast market value of the Idiopathic Pulmonary Fibrosis market?

The Idiopathic Pulmonary Fibrosis market size has grown strongly in recent years. The idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $4.15 billion in 2024 to $4.39 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to increasing aging population, limited treatment options, rising disease awareness, healthcare infrastructure development The idiopathic pulmonary fibrosis market size is expected to see strong growth in the next few years. It will grow to $5.74 billion in 2029 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to expanded research and development, precision medicine approach, increasing disease incidence, advancements in biomarker development, government initiatives and funding. Major trends in the forecast period include advancements in diagnostic techniques, emergence of targeted therapies, telemedicine and remote monitoring, combination therapies, advancements in lung transplantation. For further insights on the Idiopathic Pulmonary Fibrosis market, request a sample here

How is the Idiopathic Pulmonary Fibrosis market segmented?

The idiopathic pulmonary fibrosis market covered in this report is segmented –
1) By Drug Type: Nintedanib, Pirfenidone, Other Drug Types
2) By Mode Of Action: Antifibrotic Agents, Tyrosine Kinase Inhibitors, Other Modes Of Action
3) By Route Of Administration: Oral, Parenteral
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Providers
5) By End Users: Hospitals And Clinics, Other End Users Subsegments:
1) By Nintedanib: Indications, Dosage Forms, Administration Routes
2) By Pirfenidone: Indications, Dosage Forms, Administration Routes
3) By Other Drug Types: Specific Agents Or Classes, Emerging Therapies, Combination Therapies For further insights on the Idiopathic Pulmonary Fibrosis market, request a sample here

Which region has the largest share of the Idiopathic Pulmonary Fibrosis market? What are the other regions covered in the report?

North America was the largest region in the idiopathic pulmonary fibrosis market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the idiopathic pulmonary fibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa For further insights on the Idiopathic Pulmonary Fibrosis market, request a sample here.

Who are the major players in the Idiopathic Pulmonary Fibrosis market?

What are the key trends in the Idiopathic Pulmonary Fibrosis market?

Major trends in the Idiopathic Pulmonary Fibrosis market include Product Innovations Expanding Access And Affordability For Patients In The Idiopathic Pulmonary Fibrosis Market. For further insights on the Idiopathic Pulmonary Fibrosis market, request a sample here.

What are the major opportunities in the Idiopathic Pulmonary Fibrosis market? What are the strategies for the Idiopathic Pulmonary Fibrosis market?

For detailed insights on the major opportunities and strategies in the Idiopathic Pulmonary Fibrosis market, request a sample here.

How does the Idiopathic Pulmonary Fibrosis market relate to the overall economy and other similar markets?

For detailed insights on Idiopathic Pulmonary Fibrosis's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Idiopathic Pulmonary Fibrosis industry?

For detailed insights on the mergers and acquisitions in the Idiopathic Pulmonary Fibrosis industry, request a sample here.

What are the key dynamics influencing the Idiopathic Pulmonary Fibrosis market growth? SWOT analysis of the Idiopathic Pulmonary Fibrosis market.

For detailed insights on the key dynamics influencing the Idiopathic Pulmonary Fibrosis market growth and SWOT analysis of the Idiopathic Pulmonary Fibrosis industry, request a sample here.